Last C$0.03 CAD
Change Today 0.00 / 0.00%
Volume 0.0
QPT On Other Exchanges
Symbol
Exchange
Venture
OTC US
As of 2:40 PM 12/12/14 All times are local (Market data is delayed by at least 15 minutes).

quest pharmatech inc (QPT) Snapshot

Open
C$0.03
Previous Close
C$0.03
Day High
C$0.03
Day Low
C$0.03
52 Week High
03/5/14 - C$0.09
52 Week Low
12/2/14 - C$0.03
Market Cap
3.3M
Average Volume 10 Days
3.5K
EPS TTM
--
Shares Outstanding
108.8M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for QUEST PHARMATECH INC (QPT)

Related News

No related news articles were found.

quest pharmatech inc (QPT) Related Businessweek News

No Related Businessweek News Found

quest pharmatech inc (QPT) Details

Quest PharmaTech Inc., a clinical stage biotechnology company, engages in the development and commercialization of oncology products. It develops a portfolio of product candidates for the treatment of cancer by combining immunotherapeutic antibodies with chemotherapy, immune-adjuvants, and photodynamic therapy. The company's lead product candidate, Oregovomab, an immunotherapeutic product for the treatment of ovarian cancer and is under a multi-center Phase IIb clinical trials in Italy and the United States. The company also develops MUC1 program that has completed phase I clinical trials for the treatment of cancer tumors; and SL052, a photosensitizer product, which is under phase I clinical trials and is intended for the treatment of prostate cancer. Quest PharmaTech Inc. has a strategic relationship with with AD Biotech Co., Ltd. The company is headquartered in Edmonton, Canada.

quest pharmatech inc (QPT) Top Compensated Officers

Chief Executive Officer, Director, Ex-Officio...
Total Annual Compensation: C$150.0K
Chief Financial Officer
Total Annual Compensation: C$100.0K
Vice President of Product Development
Total Annual Compensation: C$126.0K
Compensation as of Fiscal Year 2014.

quest pharmatech inc (QPT) Key Developments

Quest PharmaTech, Inc. Announces Board of Directors Elections

Quest PharmaTech, Inc. elected Lorne Meikle and Bin Huang to Board of Directors at its AGM held on November 10, 2014.

Quest Pharmatech Inc. Signs an Exclusive Supply and Distribution Agreement with Smart Cell Tec

Quest PharmaTech Inc. announced that it has signed an exclusive supply and distribution agreement with Smart Cell Tec for the world-wide marketing and distribution rights, excluding South Korea, for the science based, premium anti-wrinkle skin care product, Bellus Skin(TM). Bellus Skin(TM) has several unique qualities that make it an effective high end anti-wrinkle serum. The patented SP Technology in Bellus Skin(TM) enables superior penetration of the key ingredients to the lower layers of the skin surface where the effect is profound and long lasting. The SP Technology platform, developed by the Korean company, Bioceltran Co. Ltd., also has applications for other cosmetic and pharmaceutical products under development. Quest has exclusive rights to SP Technology based products. In addition, Quest recently acquired equity in Bioceltran, thereby enabling plans to create a revenue stream for Quest in the near term.

Bioceltran Co., Ltd. to License Quest PharmaTech, Inc.'s Photodynamic Therapy Technology

Quest PharmaTech Inc. signed a license agreement with Bioceltran Co. Ltd. to license Quest's photodynamic therapy (PDT) technology to Bioceltran in return for up-front license fees, milestone payments and royalties on future product sales. Subsequent to signing the license agreement, Quest purchased, (for an undisclosed amount) as a Foreign Equity Investment 38% ownership interest in existing shares of Bioceltran. The ownership interest in Bioceltran will allow Quest to take advantage of certain funding opportunities that are presently available and also to benefit from the combination of Quest's PDT and Bioceltran's PTD technologies in one company. By combining Quest's photodynamic therapy (PDT) technology and Bioceltran's protein transduction (PTD) technology, Bioceltran will develop new products for both cosmetic and oncology applications using funding capital raised in South Korea. The transaction is one part of Quest's plans to license out or transfer technologies into private companies for the purpose of better raising funds to support product development and increase shareholder value.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
QPT:CN C$0.03 CAD 0.00

QPT Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for QPT.
View Industry Companies
 

Industry Analysis

QPT

Industry Average

Valuation QPT Industry Range
Price/Earnings 59.9x
Price/Sales -- Not Meaningful
Price/Book NM Not Meaningful
Price/Cash Flow 65.6x
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact QUEST PHARMATECH INC, please visit www.questpharmatech.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.